The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | The role of complement activation in complications of sickle cell disease
Lucia De Franceschi, MD, University of Verona, Verona, Italy, outlines the role of complement activation in sickle cell disease (SCD) complications. Linked to a more severe phenotype, complement activation emerges as a promising therapeutic target currently under evaluation in three ongoing clinical trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Bristol Myers Squibb, Agios
Board of Directors/Advisory Committee: F. Hoffmann-La Roche Ltd, Basel
